Hepatitis B Foundation awards UT School of Public Health professor

January 08, 2010

HOUSTON - (Jan. 8, 2010) - R. Palmer Beasley, M.D., Ashbel Smith Professor at The University of Texas School of Public Health, has been awarded the Hepatitis B Foundation's Distinguished Scientist Award 2010.

"The HBV vaccine, the first cancer vaccine, provides long-term protection against hepatitis B infection, which is responsible for a large proportion of liver cancer in the world. Ultimately, HBV can be eradicated," said Beasley. "This honor from the Hepatitis B Foundation provides another tool to encourage the world to use the vaccine vigorously."

For more than 18 years, Beasley served as dean of the UT School of Public Health. Beasley has pioneered work in perinatal hepatitis B virus transmission, which showed that mother-infant transmission was the most important factor in sustaining hepatitis B virus infection in Asia. He also did the definitive research that proved that hepatitis B causes primary liver cancer and led the global effort to convince the World Health Organization to establish the HBV vaccine as the first human cancer vaccine.

"Dr. Beasley's contributions to understanding the link between hepatitis B and liver cancer have saved thousands of lives. His work not only transformed our understanding of the cause of liver cancer, but then spearheaded the solution through vaccination," said Roberta B. Ness, M.D., dean of the UT School of Public Health. "We are certainly proud to call him one of our own."

This award is the highest scientific honor awarded by the foundation in recognition and appreciation for the research of hepatitis B.
-end-


University of Texas Health Science Center at Houston

Related Hepatitis Articles from Brightsurf:

Busting Up the Infection Cycle of Hepatitis B
Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the ''spiky ball'' that encloses its genetic blueprint.

Liver cancer: Awareness of hepatitis D must be raised
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma.

Hepatitis B: New therapeutic approach may help to cure chronic hepatitis B infection
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B.

Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis.

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.

Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.

How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.

New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.

High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.

Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.

Read More: Hepatitis News and Hepatitis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.